BRISTOL MYERS SQUIBB CO
For the period ended Jun 30, 2026. Filed Jul 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Summary of Abbreviated Terms
Bristol-Myers Squibb Company and its consolidated subsidiaries may be referred to as Bristol Myers Squibb, BMS, the Company, we, our or us in this Quarterly Report on Form 10-Q, unless the context otherwise indicates. Throughout this Quarterly Report on Form 10-Q we have used terms which are defined below:
| 2025 Form 10-K | Annual Report on Form 10-K for the fiscal year ended December 31, 2025 | Merck | Merck & Co., Inc., Rahway, NJ, USA |
|---|---|---|---|
| 2seventy bio | 2seventy bio, Inc. | MF | myelofibrosis |
| ANDA | Abbreviated New Drug Application | Mirati | Mirati Therapeutics, Inc. |
| AstraZeneca | AstraZeneca PLC | MZL | marginal zone lymphoma |
| AOCL | Accumulated other comprehensive loss | NDA | New Drug Application |
| BioArctic | BioArctic AB | NHL | Non-Hodgkin's Lymphoma |
| BioNTech | BioNTech SE | oHCM | Obstructive Hypertrophic Cardiomyopathy |
| Celgene | Celgene Corporation | Ono | Ono Pharmaceutical Co., Ltd |
| CERCLA | U.S. Comprehensive Environmental Response, Compensation and Liability Act | PD-1 | programmed cell death protein 1 |
| cHL | classical Hodgkins Lymphoma | PD-L1 | programmed death-ligand 1 |
| CRC | colorectal cancer | PDUFA | Prescription Drug User Fee Act |
| CVR | Contingent value right | Pfizer | Pfizer, Inc. |
| Dr. Reddy's Laboratories | Dr. Reddy’s Laboratories, Limited and Dr. Reddy’s Laboratories, Inc. | PFS | progression-free survival |
| EC | European Commission | PsA | psoriatic arthritis |
| EPS | earnings per share | Quarterly Report on Form 10-Q | Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 |
| ESCC | esophageal squamous cell carcinoma | R&D | research and development |
| EU | European Union | RDFV | readily determinable fair values |
| Evotec | Evotec SE | REMS | risk evaluation and mitigation strategy |
| Exchange Act | the Securities Exchange Act of 1934 | Roche | F. Hoffman-La Roche & Co. |
| FASB | Financial Accounting Standards Board | RRMM | relapsed or refractory multiple myeloma |
| FDA | U.S. Food and Drug Administration | Sanofi | Sanofi S.A. |
| GAAP | generally accepted accounting principles | SAR | Special Administrative Region |
| GTN | gross-to-net | SEC | U.S. Securities and Exchange Commission |
| HCM | hypertrophic cardiomyopathy | sNDA | supplemental New Drug Application |
| Hengrui | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | SPC | Supplementary Protection Certificate |
| HHS | Health and Human Services | SystImmune | SystImmune, Inc. |
| IPRD | in-process research and development | TNBC | triple negative breast cancer |
| IRA | Inflation Reduction Act of 2022 | UK | United Kingdom |
| IRS | Internal Revenue Service | U.S. | United States |
| IT | Information Technology | VAT | value added tax |
| MCL | mantle cell lymphoma | VEGF-A | Vascular endothelial growth factor A |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.